Syprine

Syprine

Syprine Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Patient experience with trientine hydrochloride is limited (see CLINICAL PHARMACOLOGY). Patients receiving SYPRINE should remain under regular medical supervision throughout the period of drug administration. Patients (especially women) should be closely monitored for evidence of iron deficiency anemia.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

SYPRINE is indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine. Clinical experience with SYPRINE is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. SYPRINE and penicillamine cannot be considered interchangeable. SYPRINE should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects.

Unlike penicillamine, SYPRINE is not recommended in cystinuria or rheumatoid arthritis. The absence of a sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. In 15 patients with rheumatoid arthritis, SYPRINE was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment.

SYPRINE is not indicated for treatment of biliary cirrhosis.

History

There is currently no drug history available for this drug.

Other Information

Trientine hydrochloride is N,N'-bis (2-aminoethyl)-1,2-ethanediamine dihydrochloride. It is a white to pale yellow crystalline hygroscopic powder. It is freely soluble in water, soluble in methanol, slightly soluble in ethanol, and insoluble in chloroform and ether.

The empirical formula is C6H18N4•2HCl with a molecular weight of 219.2. The structural formula is:

          NH2(CH2)2NH(CH2)2NH(CH2)2NH2•2HCl

Trientine hydrochloride is a chelating compound for removal of excess copper from the body. SYPRINE1 (Trientine Hydrochloride) is available as 250 mg capsules for oral administration. Capsules SYPRINE contain gelatin, iron oxides, stearic acid, and titanium dioxide as inactive ingredients.

1
Registered trademark of ATON PHARMA, INC.
COPYRIGHT © 2010 ATON PHARMA, INC.
All rights reserved

Syprine Manufacturers


  • Aton Pharma, Inc.
    Syprine (Trientine Hydrochloride) Capsule [Aton Pharma, Inc.]
  • Valeant Pharmaceuticals North America Llc
    Syprine (Trientine Hydrochloride) Capsule [Valeant Pharmaceuticals North America Llc]

Login To Your Free Account